A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
Status:
Not yet recruiting
Trial end date:
2023-04-11
Target enrollment:
Participant gender:
Summary
The main aim of the study is to check if treatment with maribavir can protect Japanese people
against Cytomegalovirus (CMV) infection, and to check side effect from the study treatment
and how much maribavir participants can take without getting side effects from it.
Japanese recipients of a hematopoietic stem cell transplant (HSCT) or solid organ transplant
(SOT) will take Maribavir tablets two times a day for 8 weeks in this study.
During the study, participants will visit their study clinic 18 times as a maximum.